937636-52-7 Usage
Molecular Weight
273.13 g/mol
Structure
Morpholine derivative with a benzyl group
Bromo (Br) group attached at position 2 of the benzyl ring
Hydroxyl (OH) group attached at position 5 of the benzyl ring
Synthesis
Used in the synthesis of various pharmaceuticals and organic compounds
Applications
Drug Synthesis: Commonly used as a building block in pharmaceutical production
Agrochemicals: Utilized in the synthesis of agrochemicals due to its versatile reactivity
Biological Activity
Pharmacological Studies: Investigated for potential therapeutic uses in treating diseases and disorders
Pesticidal Properties: Studied for its effectiveness as a pesticide
Versatile Reactivity
Due to its unique structure, it exhibits versatile reactivity in chemical reactions
Potential
Valuable tool in the development of new chemical compounds for various applications
Check Digit Verification of cas no
The CAS Registry Mumber 937636-52-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,7,6,3 and 6 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 937636-52:
(8*9)+(7*3)+(6*7)+(5*6)+(4*3)+(3*6)+(2*5)+(1*2)=207
207 % 10 = 7
So 937636-52-7 is a valid CAS Registry Number.
937636-52-7Relevant academic research and scientific papers
Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD
De Savi, Chris,Cox, Rhona J.,Warner, Daniel J.,Cook, Anthony R.,Dickinson, Mark R.,McDonough, Amy,Morrill, Louis C.,Parker, Beth,Andrews, Glen,Young, Simon S.,Gilmour, Peter S.,Riley, Rob,Dearman, Matthew S.
, p. 4661 - 4676 (2014/07/07)
Oral phosphodiesterase 4 (PDE4) inhibitors, such as cilomilast and roflumilast, have been shown to be efficacious against chronic obstructive pulmonary disease (COPD). However, these drugs have been hampered by mechanism-related side effects such as nause
PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES
-
Page/Page column 45-46, (2009/12/27)
The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.
